Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The study will include 10 adult patients with cystic fibrosis. The aim of the study is to
evaluate whether Tobramycin 300 mg aerosol once-a-day for 28 days can reduce the bacterial
load in the airways. Secondary end-point is the evaluation of variation in bacterial
susceptibility during and at the end of study period.